Botulinum neurotoxin 3D structures: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 12: | Line 12: | ||
*Type A Light Chain residues 1-425 | *Type A Light Chain residues 1-425 | ||
**[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]] - CbCBN LC + Zn<br /> | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]], [[7ky2]], [[7kyf]], [[7kyh]] - CbCBN LC + Zn<br /> | ||
**[[5vgv]] - CbCBN LC + Cu<br /> | **[[5vgv]] - CbCBN LC + Cu<br /> | ||
**[[5vgx]] - CbCBN LC + Hg<br /> | **[[5vgx]] - CbCBN LC + Hg<br /> | ||
| Line 21: | Line 21: | ||
**[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | **[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | ||
**[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | **[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | ||
**[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]] – CbCBN LC + inhibitor + Zn<br /> | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]], [[6xcb]], [[6xcc]], [[6xce]], [[6xcf]], [[7n18]] – CbCBN LC + inhibitor + Zn<br /> | ||
**[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | ||
**[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | **[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | ||
**[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | **[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | ||
**[[3k3q]] - CbCBN LC + antibody + Zn<br /> | **[[3k3q]] - CbCBN LC + antibody + Zn<br /> | ||
**[[7l6v]], [[7lzp]], [[7m1h]] - CbCBN LC + nanobody + Zn<br /> | |||
*Type A translocation domain residues 547-871 | *Type A translocation domain residues 547-871 | ||
| Line 32: | Line 33: | ||
**[[6mhj]] - CbCBN (mutant) <br /> | **[[6mhj]] - CbCBN (mutant) <br /> | ||
*Type A receptor-binding domain residues 871-1296 | *Type A receptor-binding or heavy chain domain residues 871-1296 | ||
**[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]] – CbPBN <br /> | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]], [[6f0o]], [[6f0p]], [[6twp]], [[6two]], [7dvl]], [[7z5t]], [[8alp]] – CbPBN <br /> | ||
**[[4iqp]] – CbPBN (mutant)<br /> | **[[4iqp]] – CbPBN (mutant)<br /> | ||
**[[7qpt]], [[7qpu]], [[7z5s]], [[8agk]] – CbPBN + oligosaccharide <br /> | |||
**[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | **[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | ||
**[[8jle]], [[8jlf]], [[8jlg]] – CbCBN + synaptic vesicle glycoprotein 2A – Cryo EM<br /> | |||
**[[8jlh]], [[8js8]], [[8k77]] – CbCBN + synaptic vesicle glycoprotein 2A + drug – Cryo EM<br /> | |||
**[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | **[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | ||
**[[5jmc]] – CbCBN (mutant) + synaptic vesicle glycoprotein 2C<br /> | **[[5jmc]] – CbCBN (mutant) + synaptic vesicle glycoprotein 2C<br /> | ||
| Line 47: | Line 51: | ||
**[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | **[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | ||
*'''Type B''' | *'''Type B residues 1-1291''' | ||
**[[7qfq]] – CbCBN (mutant) – Cryo EM<br /> | |||
**[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | ||
**[[6g5f]] – CbCBN + synaptotagmin-1<br /> | **[[6g5f]] – CbCBN + synaptotagmin-1<br /> | ||
| Line 60: | Line 65: | ||
**[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | **[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | ||
**[[7na9]], [[7t5f]] - CbCBN LC + Zn + nanobody<br /> | |||
*Type B Light+Heavy Chain translocation domain residues 1-858 | *Type B Light+Heavy Chain translocation domain residues 1-858 | ||
| Line 67: | Line 73: | ||
*Type B receptor-binding domain residues 857-1291 | *Type B receptor-binding domain residues 857-1291 | ||
**[[1z0h]] – CbCBN <br /> | **[[1z0h]], [[6zvm]] – CbCBN <br /> | ||
**[[6g5k]] - CbCBN + synaptotagmin-1 peptide<br /> | **[[6g5k]], [[6zvn]] - CbCBN + synaptotagmin-1 peptide<br /> | ||
**[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | **[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | ||
**[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | **[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | ||
| Line 105: | Line 111: | ||
*Type E | *Type E | ||
**[[7qfp]] – CbCBN – Cryo EM<br /> | |||
**[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | **[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | ||
**[[7k7y]], [[7k84]] - CbCBN + VHH<br /> | |||
**[[7ovw]] – CbPBN + oligosaccharide <br /> | |||
*Type E Light Chain | *Type E Light Chain | ||
| Line 111: | Line 120: | ||
**[[1t3a]] - CbCBN LC + Zn<br /> | **[[1t3a]] - CbCBN LC + Zn<br /> | ||
**[[1t3c]], [[1zkw]], [[1zkx]], [[1zl5]], [[1zl6]], [[1zn3]] – CbCBN (mutant) + Zn<br /> | **[[1t3c]], [[1zkw]], [[1zkx]], [[1zl5]], [[1zl6]], [[1zn3]] – CbCBN (mutant) + Zn<br /> | ||
*Type E heavy Chain | |||
**[[7uie]] – CbCBN HC + synaptic vesicle glycoprotei<br /> | |||
*Type F Light Chain | *Type F Light Chain | ||
| Line 128: | Line 141: | ||
**[[2vxr]], [[3mpp]] - CbCBN <br /> | **[[2vxr]], [[3mpp]] - CbCBN <br /> | ||
*Type H Light Chain | |||
**[[6bvd]] - CbCBN LC + Zn<br /> | |||
*Type X Light Chain | *Type X Light Chain | ||
| Line 133: | Line 150: | ||
**[[6f4e]] - CbCBN LC<br /> | **[[6f4e]] - CbCBN LC<br /> | ||
**[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | **[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | ||
**[[7kz7]] - CbCBN LC (mutant) + Zn<br /> | |||
*Type X | |||
**[[8qft]] - CbCBN <br /> | |||
}} | }} | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Latest revision as of 14:28, 10 December 2024
3D structures of botulinum neurotoxin3D structures of botulinum neurotoxin
Updated on 10-December-2024